Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advent Gains High-Potential ART Business Through Bharat Buy

Deal Gives Exit To Other PE Groups

Executive Summary

With a majority stake in Bharat Serums, Advent gains access to biologics in gynecology and high-potential assisted reproductive technology. The deal also provides an exit to two other PE funds - OrbiMed and Kotak.

You may also be interested in...



Bharat Serums Takes Shot At Ulinastatin For COVID-19 Respiratory Distress

Private equity-controlled Bharat Serums and Vaccines gets go-ahead in India for COVID-19-related trials with ulinastatin, an existing sepsis therapy for which it is the leading player in the country. Management also outlines how the firm is ensuring business continuity during this challenging phase.

A Decade’s Deals In Indian Pharma Point To 2020 Trends

A look at corporate acquisitions and private equity deals in the Indian pharmaceutical industry over 2010-2019 reveals some trends, lessons and targets for possible activity in 2020.

2019 India Deals - Sell, License, Brands And China

Scrip highlights the key transactions involving Indian firms in 2019. Divestments and licensing were among the prominent themes that dotted the deal landscape in the year gone by.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel